Recombinant Rat Erlin-2 (Erlin2)

What is the molecular structure and cellular localization of Erlin-2?

Erlin-2 is a member of the SPFH domain-containing family of lipid raft-associated proteins. The protein has an observed molecular weight of approximately 43kDa, though its calculated molecular weight is 38kDa, suggesting post-translational modifications . It is primarily localized to lipid rafts of the endoplasmic reticulum (ER), where it performs several specialized functions. Structurally, Erlin-2 contains a region between amino acids 50-150 that has been used as an immunogen for antibody production, indicating this region contains accessible epitopes . The protein's SPFH domain is critical for its association with ER membrane microdomains.

What are the primary cellular functions of Erlin-2?

Erlin-2 plays a critical role in inositol 1,4,5-trisphosphate (IP3) signaling by mediating ER-associated degradation of activated IP3 receptors . Beyond this canonical role, research has revealed that Erlin-2 is involved in several other cellular processes:

• Regulation of lipid metabolism through interaction with Sterol Regulatory Element-Binding Protein 1c (SREBP1c), the key lipogenic trans-activator

• Protection of cells from ER stress-induced cell death

• Modulation of the unfolded protein response (UPR) pathway

• Interaction with Insulin-induced Gene 1 (INSIG1) to regulate SREBP1c activation

How is Erlin-2 expression regulated in normal and disease states?

The UPR pathway, specifically through the IRE1α/XBP1 axis, modulates the high-level expression of the ERLIN2 protein . This regulation occurs through the IRE1α RNase activity, rather than its kinase activity . Under ER stress conditions, cancer cells can upregulate the IRE1α/XBP1 UPR pathway while simultaneously repressing the ER stress-induced apoptotic pathway through CHOP . This allows for stress adaptation and apoptosis resistance. In breast cancer, ERLIN2 gene amplification leads to protein overexpression in both luminal and Her2 subtypes .

What are the optimal methods for detecting Erlin-2 in experimental samples?

Based on published methodologies, researchers have several validated approaches for Erlin-2 detection:

Western Blot Analysis:

• Recommended antibody dilution: 1:500 - 1:1000

• Protein loading: 25μg per lane

• Blocking buffer: 3% nonfat dry milk in TBST

• Detection system: ECL Basic Kit

• Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution

Immunohistochemistry (IHC-P):

• Recommended antibody dilution: 1:50 - 1:200

• Antigen retrieval: High pressure with 10 mM citrate buffer pH 6.0

• IHC has been validated on mouse kidney and rat ovary tissues

ELISA:

• Also validated for Erlin-2 detection though specific protocols were not detailed in the provided materials

What genetic manipulation approaches are effective for studying Erlin-2 function?

Researchers have successfully employed several genetic manipulation techniques to study Erlin-2:

Knockdown Approaches:

• Lentiviral-based shRNA systems have been effectively used to stably knockdown ERLIN2 in breast cancer cell lines, including SUM-44, SUM-52, and SUM-225

• Multiple shRNA constructs should be tested to identify the most effective sequences for knockdown

• ERLIN2 knockdown has been shown to significantly inhibit cell proliferation and anchorage-independent growth in soft agar assays

Overexpression Systems:

• Lentiviral-based overexpression systems using constructs like pLenti6/V5-ERLIN2 have been used successfully in non-transformed mammary epithelial cells (MCF10A)

• Overexpression of ERLIN2 leads to expansion of the ER compartment, which may contribute to stress resistance

• ERLIN2-overexpressing cells show increased lipid droplet accumulation

How can researchers evaluate the functional consequences of Erlin-2 manipulation?

Several functional assays have proven valuable for assessing Erlin-2's roles:

Proliferation and Transformation Assays:

• Cell proliferation assays comparing growth rates of control versus ERLIN2-manipulated cells

• Anchorage-independent growth in soft agar to assess transforming potential

• Orthotopic transplantation into mammary fat pads of nude mice to evaluate tumor growth in vivo

Stress Response Assays:

• Treatment with ER stress-inducing reagents (Tunicamycin or Thapsigargin) to assess cell survival

• Evaluation of responses to chemotherapeutic drugs and proteasome inhibitors like Bortezomib

Lipid Metabolism Analysis:

• Quantification of cytosolic lipid droplets and triglyceride content

• Assessment of SREBP1c activation and fatty acid synthase (FASN) levels

What is the significance of Erlin-2 in breast cancer progression?

Erlin-2 has emerged as an important factor in breast cancer:

Gene Amplification and Overexpression:

Transforming Properties:

• ERLIN2 is required for cell proliferation and maintenance of transforming phenotypes in aggressive, ERLIN2-amplified breast cancer

• Knockdown of ERLIN2 inhibits tumor growth in orthotopic mouse models using SUM-225 breast cancer cells

Stress Adaptation Mechanism:

• ERLIN2 facilitates breast cancer cell adaptation to ER stress by supporting cell growth and protecting cells from ER stress-induced death

• Overexpression promotes lipid droplet accumulation, helping cancer cells gain growth advantages and protection from stress-induced apoptosis

What is known about Erlin-2's role in neurological disorders?

Mutations in the ERLIN2 gene are a cause of spastic paraplegia-18 (SPG18) . This neurological disorder is characterized by progressive lower limb spasticity and weakness. While the search results didn't provide detailed mechanisms, the localization of Erlin-2 to the ER and its role in protein quality control suggest that mutations could disrupt neuronal protein homeostasis, leading to cellular dysfunction and neurodegeneration.

How might Erlin-2 be targeted therapeutically in disease contexts?

Research suggests several potential therapeutic approaches targeting Erlin-2:

Combination with Proteasome Inhibitors:

• SUM-225 breast cancer cells with ERLIN2 knockdown exhibited significantly lower Bortezomib IC50 values compared to control cells

• This suggests a synergistic cooperation between ERLIN2 inhibition and proteasome inhibition that could be therapeutically exploited

Targeting the UPR Pathway:

• Since the IRE1α/XBP1 axis regulates ERLIN2 expression, targeting this pathway could indirectly modulate ERLIN2 levels

• Combinations of UPR modulators with ERLIN2 inhibition might enhance therapeutic efficacy

Lipid Metabolism Intervention:

• Given ERLIN2's role in lipid metabolism and SREBP1c activation, combining ERLIN2 inhibition with lipid synthesis inhibitors might represent another therapeutic strategy

How does Erlin-2 regulate the activation of lipogenic transcription factors?

Erlin-2 plays a key role in maintaining the lipogenic phenotype of breast cancer cells through several mechanisms:

SREBP1c Regulation:

• ERLIN2 regulates activation of Sterol Regulatory Element-Binding Protein 1c (SREBP1c), the key lipogenic trans-activator

• This regulation occurs through ERLIN2's interaction with Insulin-induced Gene 1 (INSIG1)

• INSIG1 normally retains SREBP precursors in the ER, preventing their activation

• ERLIN2 may modulate this retention, facilitating SREBP1c processing and activation

Lipid Droplet Formation:

• ERLIN2-amplified breast cancer cell lines, such as SUM225 and SUM44, possess abundant cytosolic lipid droplets

• ERLIN2 knockdown significantly reduces cytosolic lipid droplet and cellular triglyceride contents

• This suggests ERLIN2 promotes de novo lipogenesis, which may contribute to cancer cell survival

What is the relationship between Erlin-2 and the unfolded protein response (UPR)?

The relationship between Erlin-2 and the UPR is bidirectional and complex:

UPR Regulation of Erlin-2:

• The IRE1α/XBP1 axis of the UPR pathway modulates ERLIN2 protein expression in breast epithelial cells

• This regulation specifically depends on the RNase activity of IRE1α, not its kinase activity

• This suggests that XBP1s (spliced XBP1) may directly or indirectly regulate ERLIN2 gene expression

Erlin-2 Modulation of ER Stress Response:

• Overexpression of ERLIN2 leads to expansion of the ER compartment, potentially increasing cellular capacity to handle misfolded proteins

• ERLIN2 protects breast cancer cells from ER stress-induced cell death when treated with stress-inducing agents like Tunicamycin or Thapsigargin

• Cancer cells gain stress-adaptation and apoptosis-resistance by upregulating the IRE1α/XBP1 UPR pathway while repressing the ER stress-induced apoptotic pathway through CHOP

How does Erlin-2 contribute to protein quality control beyond IP3 receptor regulation?

While Erlin-2 was initially characterized for its role in IP3 receptor degradation, recent research suggests broader functions in protein quality control:

ERAD Pathway Interactions:

• In addition to canonical ERAD functions, Erlin2 can act as a chaperone for aggregation-prone proteins

• ERLIN2 interacts with the intramembrane protease RHBDL4, which is involved in protein quality control at the ER

• This interaction may facilitate the recognition and processing of misfolded proteins beyond IP3 receptors

Non-ERAD Functions:

• Research indicates ERLIN2 unlikely functions solely as a mediator of ER-associated protein degradation (ERAD) in human breast cancer cells

• The levels of activated or polyubiquitinated IP3 receptor proteins were not changed in ERLIN2 over-expressing or knockdown breast cancer cells

• This suggests ERLIN2 has evolved additional functions beyond its canonical role in ERAD, particularly in cancer contexts

What are the most validated cellular models for studying Erlin-2 function?

Several cellular models have been validated for Erlin-2 research:

Breast Cancer Cell Lines:

• SUM-44 and SUM-52: Luminal subtype breast cancer cells with ERLIN2 amplification

• SUM-225: HER2-amplified breast cancer cell line with ERLIN2 amplification

• These models are particularly useful for studying ERLIN2's role in cancer progression

Non-transformed Mammary Epithelial Cells:

• MCF10A cells: Used with ERLIN2 overexpression to study the protein's transforming potential

• Provides a good model for assessing ERLIN2's functions in normal cellular contexts

In Vivo Models:

• Orthotopic transplantation of ERLIN2-manipulated breast cancer cells into mammary fat pads of nude mice has been validated for tumor growth studies

• SUM-225 cells have demonstrated successful growth in this model, while SUM-52 cells did not establish tumors

How can researchers effectively evaluate Erlin-2's impact on global cellular stress responses?

Comprehensive assessment of Erlin-2's role in stress responses requires multi-layered approaches:

Transcriptomic Analysis:

• RNA-seq to identify genes differentially expressed in response to ERLIN2 manipulation under normal and stress conditions

• Focus on UPR-regulated genes, lipid metabolism pathways, and cell death regulators

Proteomics Approaches:

• Global proteomic analysis to identify changes in protein expression and post-translational modifications

• Focused analysis of ER-associated proteins and UPR components

• Affinity purification coupled with mass spectrometry to identify ERLIN2 interacting partners

Metabolic Analysis:

• Lipidomics to profile changes in lipid composition following ERLIN2 manipulation

• Assessment of lipid synthesis rates and fatty acid utilization

• Evaluation of lipid droplet formation and composition

What are the emerging research directions for Erlin-2 investigation?

Several promising research directions are emerging:

Therapeutic Targeting:

• Development of specific ERLIN2 inhibitors or degraders

• Exploration of combinatorial approaches with existing therapies, particularly proteasome inhibitors

• Investigation of synthetic lethal interactions in ERLIN2-amplified cancers

Expanded Disease Relevance:

• Evaluation of ERLIN2's role in other cancer types beyond breast cancer

• Deeper investigation into its contribution to neurological disorders like SPG18

• Potential relevance to metabolic disorders given its role in lipid metabolism

Structural Biology Approaches:

• Determination of ERLIN2's three-dimensional structure to understand its mechanism of action

• Identification of critical domains for protein-protein interactions

• Structure-based design of potential inhibitors